Pluvicto Pushes Earlier in Prostate Cancer Play

Pluvicto pushes earlier in prostate cancer play

Today's biotech news covers Pluvicto's prostate cancer play, J&J's big bets on bladder, lung, and talent, and more.

Novartis reports topline outcomes from trial of Pluvicto for prostate cancer

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis of Pluvicto.The post Novartis reports topline outcomes from trial of Pluvicto for prostate cancer  appeared first on Clinical Trials Arena.

Pluvicto shows promise in combination with standard treatments

Novartis has announced that Pluvicto shows promise in patients in an earlier setting.

Novartis Announces Positive Interim Results for Pluvicto™ in Early-Stage Prostate Cancer, Meeting Primary Endpoint in Phase III PSMAddition Trial

Novartis Announces Positive Interim Results for Pluvicto™ in Early-Stage Prostate Cancer, Meeting Primary Endpoint in Phase III PSMAddition Trial (IN BRIEF) Novartis has announced that its Phase III PSMAddition trial of Pluvicto™ in combination with standard of care (SoC) has met its primary endpoint, showing a significant benefit in radiographic progression-free survival (rPFS) and a positive trend in overall survival (OS) for patients with PSM…